News >

Pembrolizumab Improves PFS in Frontline MSI-H/dMMR Colorectal Cancer

Jason M. Broderick @jasoncology
Published: Thursday, Apr 02, 2020

Dr. Roy Baynes

Roy Baynes, MD, PhD
Pembrolizumab (Keytruda) significantly improved progression-free survival (PFS) versus chemotherapy as a first-line treatment for patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (CRC), meeting 1 of the dual primary endpoints of the phase III KEYNOTE-177 trial. 

“These head-to-head data with Keytruda are the first time a single-agent, anticancer therapy, and particularly an anti–PD-1 monotherapy, achieved a statistically significant improvement in progression-free survival over chemotherapy, including the current standard of care regimen of mFOLFOX6 plus bevacizumab (Avastin), in patients with MSI-H colorectal cancer,” Roy Baynes, MD, PhD, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories, said in a press release.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication